combinations

R05DA20

Forms & Strengths

Various fixed-dose combinations including opioid antitussives (e.g., codeine, hydrocodone) combined with decongestants, antihistamines, and/or expectorants.
Available as oral syrups, liquids, and tablets.

Adult Dosing

Dosage varies significantly based on the specific combination product formulation.
Typically 5 to 10 mL of liquid or 1 tablet every 4 to 6 hours as needed for cough.
Do not exceed maximum daily doses specified for individual active ingredients, particularly opioid components and acetaminophen if present.

Pediatric Dosing

Contraindicated in children under 6 years of age due to risk of severe respiratory depression and mortality.
For children aged 6 to 12 years, use is strictly limited and doses must be calculated based on the specific active components and pediatric guidelines.

Indications

Temporary relief of cough, upper respiratory symptoms, nasal congestion, and associated conditions due to the common cold or upper respiratory infections.

Mechanism of Action

Combines the central antitussive action of an opioid (suppressing the medullary cough center) with peripheral agents such as antihistamines (reducing secretions), decongestants (causing vasoconstriction), and expectorants (increasing respiratory tract fluid).

Contraindications

Hypersensitivity to any active component.
Children under 6 years of age.
Post-operative pain management following tonsillectomy and/or adenoidectomy in children.
Significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, or hypercapnia.
Known or suspected paralytic ileus.

Adverse Reactions

Central nervous system depression, somnolence, dizziness, and sedation.
Respiratory depression.
Gastrointestinal disturbances including constipation, nausea, and vomiting.
Anticholinergic effects from antihistamine components, such as dry mouth, blurred vision, and urinary retention.

Drug Interactions

Concomitant use with CNS depressants, alcohol, sedatives, tranquilizers, or general anesthetics may cause additive CNS depression, respiratory depression, hypotension, profound sedation, or coma.
Monoamine oxidase inhibitors (MAOIs) may interact severely with certain components (e.g., decongestants or opioids), leading to hypertensive crises or unpredictable central nervous system excitation.
CYP3A4 and CYP2D6 inhibitors or inducers may alter the metabolism of opioid components.

Curated Content: Needs Vetting Before Put to Clinical Use